Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimizing Pazopanib Exposure in RCC Patients Through Therapeutic Drug Monitoring Followed by Intrapatient Dose Escalation

NCT02089802 is registered in ClinicalTrials.gov with Interessenverband zur Qualitätssicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland e. as lead sponsor.

NCT NCT02089802
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02089802 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimizing Pazopanib Exposure in RCC Patients Through Therapeutic Drug Monitoring Followed by Intrapatient Dose Escalation
Lead sponsor
Interessenverband zur Qualitätssicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland e.
Phase
Phase 2
Overall status
Terminated
Start date
February 25, 2014
Completion date
March 22, 2016
Enrollment
6 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced renal cell carcinoma, metastatic renal cell carcinoma